We are still only in January and Celgene and Sanofi have already made a combined $20B in M&A deals.
We are still only in January and Celgene and Sanofi have already made a combined $20B in M&A deals. Sanofi has acquired Biogen‘s spinoff Bioverativ for about $11.6 billion. The third time is the charm apparently, having lost out on bids for Medivation to Pfizer and to J&J for Actelion. A little more than two years after taking a $1 billion stake in Juno, Celgene has snapped up the rest of the company in a $9 billion deal.
Here’s a roundup of these stories and other top deals and partnerships from the past month.
- Deal Spree Continues as Celgene Nabs Juno in $9B Deal
- Sanofi CEO Finally Scores With $11.6B Buyout of Biogen’s Spinoff Bioverativ
- No Deal for Novo as Sanofi Swoops in With $4.85B Win for Ablynx
- Biotech Startup Formed by 4 Ex-Pfizer Employees Inks Deal With Former Employer
- Surprise: Biogen Finally Makes a Buy, But Only Spends a Measly $217M
Read More From Karl Thiel:
Get Ready for the M&A Explosion
